The MET-targeting anticancer drug 'Tepmetko' has passed the review process for reimbursement listing three years after being approved in South Korea..

Sources said that Merck Korea's Tepmetko (tepotinib), a treatment for patients with topically advanced or metastatic non-small cell lung cancer (NSCLC) harboring mesenchymal-epithelial transition factor gene exon 14 (METex14) skipping mutations, has passed the Drug Reimbursement Evaluation Committee (DREC) review of the Health Insurance Review and Assessment Service (HIRA). Now, the remaining procedure is the drug price negotiations with the National Health Insurance Service (NHIS).

Tepmetko received domestic approval in 2021 at the same t